Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | PTGES | O14684 | 1/20 | 0.66 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473954 | 0.91 | ABCB1 (0.66) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL1101913 | 0.85 | PTGS2 (0.71) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL9519146 | 0.83 | PTGS2 (0.69) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL10947779 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL10947785 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL4542475 | 0.83 | PTGS2 (0.75) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL17836951 | 0.82 | PTGS2 (0.71) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL11833600 | 0.82 | PTGS2 (0.67) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL13391124 | 0.81 | PTGS2 (0.66) | PTGS2PTGS1AKR1C3AKR1C2PPARG | |
| SCHEMBL2739295 | 0.81 | PTGS2 (0.66) | PTGS2PTGS1AKR1C3AKR1C2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| EP-2342179-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | Semmelweis Egyetem (HU) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| US-5250552-A | 3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5143927-A | Antiallergens; lipoxygenase and cyclooxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5112846-A | Nonsteroidal antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
| US-5075330-A | N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-12-24 | — | — | US | disclosed |
| US-4981865-A | N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | PTGS2 3867/4885PTGS1 2015/4885AKR1C3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.